Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Abliva starts late-stage study with KL1333

Abliva

Lund-based biotech Abliva's main goal for 2022 was to initiate clinical phase II studies with lead drug candidate KL1333. The company hit their target last week with the initiation of the FALCON study, a study designed with the potential to support registration of the drug for commercialisation. BioStock interviewed Abliva CEO Ellen Donnelly to learn more about this important study.

Read the article at biostock.se:

https://www.biostock.se/en/2022/12/abliva-starts-late-stage-study-with-kl1333/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.